7.30
+0.31(+4.43%)
Currency In USD
| Previous Close | 6.99 |
| Open | 6.95 |
| Day High | 7.45 |
| Day Low | 6.62 |
| 52-Week High | 10.08 |
| 52-Week Low | 1.1 |
| Volume | 1.04M |
| Average Volume | 1.94M |
| Market Cap | 265.01M |
| PE | -4.08 |
| EPS | -1.79 |
| Moving Average 50 Days | 6.81 |
| Moving Average 200 Days | 3.7 |
| Change | 0.31 |
If you invested $1000 in Immuneering Corporation (IMRX) since IPO date, it would be worth $415.01 as of November 23, 2025 at a share price of $7.3. Whereas If you bought $1000 worth of Immuneering Corporation (IMRX) shares 3 years ago, it would be worth $1,153.24 as of November 23, 2025 at a share price of $7.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
GlobeNewswire Inc.
Nov 04, 2025 9:05 PM GMT
- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday, November 12, 2025, at 4:30 pm ET - NEW YORK, Nov. 0
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
GlobeNewswire Inc.
Sep 26, 2025 8:01 PM GMT
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on S
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
GlobeNewswire Inc.
Sep 25, 2025 4:08 AM GMT
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,914 shares of